N/A N=129 Blinded Dry Mouth Spray Crossover Study
Xerostomia · Head and Neck Cancer · Xerostomia Following Radiotherapy
Primary: Oral Dryness — 45.5; 46.6; 52.76; 54.1 units on a scale — p=<0.501
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Trial of Parotid Sparing Whole Brain Radiation
Xerostomia
Primary: Xerostomia One Month After Completion of Treatment — 5; 7; 1; 6 Participants
Phase 2 N=30 Mesenchymal Stemcells for Radiation Induced Xerostomia
Xerostomia
Primary: Number of Participants With Adverse Events as a Measure of Safety — 0; 0 participants
Phase 2 N=49 Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer
Head and Neck Cancer · Radiation Toxicity · Xerostomia
Primary: Number of Patients Scored as Having the Surgical Technique of Submandibular Salivary Gland Transfer Performed "Per Protocol" — 34 participants
N/A N=258 Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer
Radiation-Induced Xerostomia · Head and Neck Cancer · Radiation Toxicity
Primary: Xerostomia Questionnaire Scores — 57.3; 50.6; 55.0; 55.2 score on a scale 0-80 — p=0.0167
Phase 2 N=68 Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
Head and Neck Cancer · Oral Complications of Radiation Therapy · Radiation Toxicity
Primary: Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered — 9 participants
Phase 3 N=196 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Xerostomia
Primary: Phase II: Treatment Compliance (Number of Compliant Patients) — 12; 44 Participants
Phase 2 N=5 A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy
Mucositis · Head and Neck Cancer
Primary: Number of Participants With Adverse Events (AEs) — 2; 3; 0; 2 participants
N/A N=23 Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC
Squamous Cell Carcinoma of the Head and Neck
Primary: Grade of Xerostomia — 1.14; 1.17 units on a scale
N/A N=11 Does Craniosacraltherapy Combined With Exercises That Focuses om Respiration and Posture in the Upper Body Have an Effect on Xerostomia and Other Late Sequelae on People Who Has Been Suffering From Cancer in Mouth and Throat?
Xerostomia Following Radiotherapy · Xerostomia Following in Neck or Head After Cancer Surgery · Other Late Sequelae Following Radiotherapy and Cancer Surgery in Neck or Head
Primary: Xerostomia Questionnaire — 8; 46.4 score on a scale
N/A N=39 Clinical Evaluation of Oral Rinse for Xerostomia
Xerostomia
Primary: Change in Dry Mouth Symptom by Visual Analog Scale at 14 Days From Baseline — 10.1; 11.6; 13.0 mm
Phase 3 N=185 Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Xerostomia · Depression · Hypertension
Primary: Dry Mouth Questionnaire (DMQ) — 3.4; 1.4 units on a scale
N/A N=42 Clinical Evaluation of MucoPEG™ for Xerostomia
Dry Mouth · Xerostomia
Primary: Change in VAS for Mouth Dryness — -0.8; -0.7; -1.5; -0.4 score on a scale — p=<0.01
N/A N=31 NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy
Xerostomia
Primary: Change in Percentage of Time With CPAP (Continuous Positive Airway Pressure) Usage — -5.09; 11.67 percentage of time
N/A N=80 Optimized Intensity Modulated Irradiation for Head and Neck Cancer
Head and Neck Cancer
Primary: Percentage of Participants With Grade 0-1 Observer-rated Dysphagia — 94 percentage of participants
Phase 2 N=50 Herbal Mouthrinse for Oral Mucositis Study
Oral Mucositis
Primary: Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily…
N/A N=66 Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
KERATOCONJUNCTIVITIS SICCA · XEROSTOMIA · SICCA SYNDROME
Primary: The Xerostomia Inventory — 40.2; 39.3 units on a scale — p=0.05
N/A N=25 Exploratory Study on Effect of Whitening Agent With Emulsion Gel in Xerostomic Population
Xerostomia
Primary: Subjective Perception of Mouth Dryness — 6.92; 6.46; 4.21; 3.46 units on a scale — p=.45
Phase 2 N=6 A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
Head and Neck Cancer
Primary: Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03…
Phase 2 N=34 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Mucositis · Oral Complications · Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Primary: Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Total Score Area Under the Curve (AUC) — 40.9; 27.2 score on a scale — p=0.1232
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
N/A N=137 Improvement of Dry Mouth Sufferers After Using an Experimental Dry Mouth Rinse Compared to a Water Control
Dry Mouth
Primary: Response to "Relieving the Discomfort of Dry Mouth" From the Modified PPAQ I 4- and 6-hours Post-use on Day 1 of Treatment — 2.51; 3.26; 3.43 score on a scale
N/A N=16 Effects of an External Oral Irrigation Device on Patients With Dry Mouth
Xerostomia
Primary: Change in Oral Health Related Quality of Life (OHRQoL) — 10.2 score on a scale
Phase 2 N=40 Cox-2 Inhibition in Radiation-induced Oral Mucositis
Oral Mucositis
Primary: Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy — 1.42; 1.36 units on a scale
N/A N=19 Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Oral Mucositis · Oral Cancer
Primary: Oral Mucositis Severity - WHO Scale — 3; 3; 0; 0 participants
Phase 3 N=94 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients
Squamous Cell Carcinoma of Nasopharynx · Squamous Cell Carcinoma of Oropharynx · Squamous Cell Carcinoma of Hypopharynx
Primary: Incidence and / or Severity of Oral Mucositis — 19; 3 Grade 3-4 oral mucositis — p=0.05
N/A N=76 Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
Dysphagia · Pain · Stage I Oropharyngeal Squamous Cell Carcinoma
Primary: Pain Visual Analogue Scale (VAS) Score Measured at 10-point Scale — 7.4; 6.8; 6.0; 6.4 units on a scale — p=0.25
Phase 4 N=100 Effect of Korean Red Ginseng (KRG) on Dry Mouth
Xerostomia
Primary: Visual Analogue Scale of Subjective Dry Mouth — 5.21; 5.03 cm — p=<0.05
Phase 2 N=60 Green Tea Lozenges for the Management of Dry Mouth
Xerostomia · Sjogren Syndrome · Dry Mouth
Primary: Change in Salivary Flow From Baseline — 0.17; 0.10; 0.66; 0.04 ml/min
N/A N=30 Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer
Head and Neck Cancer
Primary: Time Until the Maximum Oral Mucositis Measured From the Start of Radiation Treatment. — 34; 29 Days — p=0.9906